ArticleBMC pharmacology & toxicology2025
Impact of SLCO1B1 (rs2306283) polymorphism on personalized atorvastatin dosing in a genetically distinct South Asian cohort.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT06674044. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of SLC01B1 (rs2306283) Polymorphism on the Efficacy and Safety Profile of Atorvastatin in Pakistani Population
Who cites it
1 citing paper in PubMed.
- Reengineering statin therapy to protect skeletal muscle: nanocarrier strategies for mitigating mitochondrial dysfunction and myotoxicity.Inflammation and regeneration · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDyslipidemia is a prevalent condition in the Pakistani population, significantly contributing to coronary heart disease (CHD). Atorvastatin, a widely used hypolipidemic drug, exhibits variable efficacy and safety influenced by genetic factors. This study aimed to assess the impact of SLCO1B1 rs2306283 (A > G) polymorphism on the efficacy and safety profile of atorvastatin in the Pakistani population. MATERIALS/
methodsOne hundred dyslipidemic patients, aged 40–75, received atorvastatin 10 mg daily for one month. Blood samples were collected on days 0 and 28 to measure lipid profiles and creatinine kinase (CK). Genotyping for rs2306283 (388 A> G) polymorphism was performed, and myopathy was evaluated using the Statin Associated Muscle Symptoms (SAMS) clinical index tool and CK levels.
resultsThe minor allele frequency of rs2306283 was 12%. Only the AA (76%) and AG (24%) genotypes were observed; the GG genotype was absent. Atorvastatin significantly improved lipid parameters; however, no association was observed between rs2306283 polymorphism and lipid-lowering efficacy. A significant association was found with myopathy, with an incidence of 18.4% in patients with the AA genotype and 0% in those with the AG genotype. The G allele demonstrated a protective effect, as it was completely absent in the myopathy group. No significant elevation in CK levels was associated with myopathy.
conclusionsThe SLCO1B1 rs2306283 polymorphism does not affect atorvastatin’s lipid-lowering efficacy; however, individuals with the AG genotype exhibit a significantly reduced risk of statin-induced myopathy in the Pakistani population. These findings support the potential role of pharmacogenetic screening in enhancing the safety of statin therapy. CLINICALTRIALS.GOV IDENTIFIER: NCT06674044, Date: 03/09/2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.